Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome

Thrombosis Research

Volumn 135, Issue 1, 2015, Pages 26-30

  Braun, Oscar Ö ^a   Bico, Besim ^a   Chaudhry, Uzma ^b,c   Wagner, Henrik ^b,c   Koul, Sasha ^a   Tydén, Patrik ^a   Scherstén, Fredrik ^a   Jovinge, Stefan ^a   Svensson, Peter J ^a   Gustav Smith, J ^a   Van Der Pals, Jesper ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Acute coronary syndrome; Antithrombotic therapy; Ticagrelor; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; TICAGRELOR; WARFARIN; ADENOSINE; FIBRINOLYTIC AGENT; TICLOPIDINE;

ACUTE CORONARY SYNDROME; AGED; AKINESIA; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SWEDEN; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UNIVERSITY HOSPITAL; UPPER JURASSIC; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; BLEEDING; BLOOD; DRUG COMBINATION; MIDDLE AGED; PATHOPHYSIOLOGY; THROMBOSIS; TREATMENT OUTCOME; VERY ELDERLY;

ACUTE CORONARY SYNDROME; ADENOSINE; AGED; AGED, 80 AND OVER; ASPIRIN; ATRIAL FIBRILLATION; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME; WARFARIN;

EID: 84922429372     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.10.016     Document Type: Article

References (31)

1. D.R. Holmes Jr., D.J. Kereiakes, N.S. Kleiman, D.J. Moliterno, G. Patti, and C.L. Grines Combining antiplatelet and anticoagulant therapies J Am Coll Cardiol 54 2009 95 109
2. D.K. Wysowski, P. Nourjah, and L. Swartz Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action Arch Intern Med 167 2007 1414 1419
3. R.C. Becker, T.W. Meade, P.B. Berger, M. Ezekowitz, C.M. O'Connor, and D.A. Vorchheimer The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 776S 814S
4. S. Silber, P. Albertsson, F.F. Aviles, P.G. Camici, A. Colombo, and C. Hamm Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur Heart J 26 2005 804 847
5. S.B. King, S.C. Smith, J.W. Hirshfeld, A.K. Jacobs, D.A. Morrison, and D.O. Williams 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines J Am Coll Cardiol 51 2008 172 209
6. Antithrombotic Trialists' Collaboration, Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients Br Med J 2002 71 86
7. D.J. Quinlan, J.W. Eikelboom, S.G. Goodman, R.C. Welsh, D.H. Fitchett, and P. Theroux Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes Eur Heart J 32 2011 2256 2265
8. S.R. Mehta, and S. Yusuf The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease Eur Heart J 21 2000 2033 2041
9. J.G. Smith, M. Wieloch, S. Koul, O.Ö. Braun, J. Lumsden, and E. Rydell Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score EuroIntervention 8 2012 672 678
10. J.M. Ruiz-Nodar, F. Marin, J.A. Hurtado, J. Valencia, E. Pinar, and J. Pineda Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis J Am Coll Cardiol 51 2008 818 825
11. P.P. Karjalainen, P. Porela, A. Ylitalo, S. Vikman, K. Nyman, and M.A. Vaittinen Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting Eur Heart J 28 2007 726 732
12. W. Dewilde, and J.T. Berg Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST) Am Heart J 158 2009 713 718
13. W.J. Dewilde, T. Oirbans, F.W. Verheugt, J.C. Kelder, B.J. De Smet, and J.P. Herrman Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Lancet 381 2013 1107 1115
14. J.D. Snoep, M.M. Hovens, J.C. Eikenboom, J.G. van der Bom, J.W. Jukema, and M.V. Huisman Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis Am Heart J 154 2007 221 231
15. P.A. Gurbel, K.P. Bliden, K. Butler, M.J. Antonino, C. Wei, and R. Teng Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study Circulation 121 2010 1188 1199
16. U. Stenestrand, and L. Wallentin Early statin treatment following acute myocardial infarction and 1-year survival JAMA 285 2001 430 436
17. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
18. R. Mehran, S.V. Rao, D.L. Bhatt, C.M. Gibson, A. Caixeta, and J. Eikelboom Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
19. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
20. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, and K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
21. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, and C. Held Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
22. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, and S. Gottlieb Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
23. G. Biondi-Zoccai, M. Lotrionte, P. Agostoni, A. Abbate, E. Romagnoli, and G. Sangiorgi Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes Int J Cardiol 150 2011 325 331
24. R. Sorensen, M.L. Hansen, S.Z. Abildstrom, A. Hvelplund, C. Andersson, and C. Jorgensen Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data Lancet 374 2009 1967 1974
25. J.S. Paikin, D.S. Wright, M.A. Crowther, S.R. Mehta, and J.W. Eikelboom Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents Circulation 121 2010 2067 2070
26. N. Sarafoff, A. Martischnig, J. Wealer, K. Mayer, J. Mehilli, and D. Sibbing Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation J Am Coll Cardiol 61 2013 2060 2066
27. M. Lamberts, G.H. Gislason, G.Y. Lip, J.F. Lassen, J. Bjerring Olesen, and A.P. Mikkelsen Antiplatelet Therapy for Stable Coronary Artery Disease in Atrial Fibrillation Patients on Oral Anticoagulant: A Nationwide Cohort Study Circulation 129 2014 1577 1585
28. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, and M. Hanna Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
29. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
30. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
31. M. Wieloch, A. Sjalander, V. Frykman, M. Rosenqvist, N. Eriksson, and P.J. Svensson Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA Eur Heart J 32 2011 2282 2289